Drug Type Biosimilar, Monoclonal antibody |
Synonyms- |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (25 Sep 2023), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ankylosing Spondylitis | JP | 25 Sep 2023 | |
Arthritis, Psoriatic | JP | 25 Sep 2023 | |
Behcet Syndrome | JP | 25 Sep 2023 | |
Colitis, Ulcerative | JP | 25 Sep 2023 | |
Crohn Disease | JP | 25 Sep 2023 | |
Plaque psoriasis | JP | 25 Sep 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | JP | 25 Sep 2023 | |
Pustular psoriasis | JP | 25 Sep 2023 | |
Rheumatoid Arthritis | JP | 25 Sep 2023 | |
Uveitis, Intermediate | JP | 25 Sep 2023 | |
Uveitis, Posterior | JP | 25 Sep 2023 |